MTOR

Signaling by target of rapamycin proteins in cell growth control.
[15755954] Microbiol Mol Biol Rev 69(1): 79-100 (2005)

Rapamycin and mTOR kinase inhibitors.
[19568796] J Chem Biol 1(1-4): 27-36 (2008)

The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
[16217558] Cell Mol Biol Lett 10(3): 479-98 (2005)

Expanding mTOR signaling.
[17680028] Cell Res 17(8): 666-81 (2007)

Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling.
[19881913] Curr Genomics 10(3): 198-205 (2009)

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
[19381454] Target Oncol 4(2): 135-42 (2009)

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.
[18566209] Mol Cancer Ther 7(6): 1347-54 (2008)

mTOR-targeted therapy of cancer with rapamycin derivatives.
[15728109] Ann Oncol 16(4): 525-37 (2005)

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.
[17545512] Clin Cancer Res 13(11): 3109-14 (2007)

The biology behind mTOR inhibition in sarcoma.
[17766661] Oncologist 12(8): 1007-18 (2007)

Upstream and downstream of mTOR.
[15314020] Genes Dev 18(16): 1926-45 (2004)

Defining the role of mTOR in cancer.
[17613433] Cancer Cell 12(1): 9-22 (2007)

TOR signaling in growth and metabolism.
[16469695] Cell 124(3): 471-84 (2006)

Microtubules, motors, and mRNA localization mechanisms: watching fluorescent messages move.
[11747806] Cell 107(6): 707-10 (2001)

TOR, a central controller of cell growth.
[11057898] Cell 103(2): 253-62 (2000)

TOR signaling: an odyssey from cellular stress to the cell growth machinery.
[15723787] Curr Biol 15(4): R139-41 (2005)

The amino acid sensitive TOR pathway from yeast to mammals.
[16684541] FEBS Lett 580(12): 2821-9 (2006)

Therapeutic targets: MTOR and related pathways.
[16969122] Cancer Biol Ther 5(9): 1065-73 (2006)

The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
[14508096] Cancer Biol Ther 2(4 Suppl 1): S169-77 (2003)

LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
[19245654] Acta Physiol (Oxf) 196(1): 65-80 (2009)

Amino acid regulation of TOR complex 1.
[18765678] Am J Physiol Endocrinol Metab 296(4): E592-602 (2009)

Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.
[19264150] Biochim Biophys Acta 1791(9): 949-55 (2009)

Eph receptor and mTOR pathway crosstalk: implications for cancer.
[20505333] Cell Cycle 9(11): 2053-4 (2010)

Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?
[17102641] Cell Cycle 5(21): 2425-9 (2006)

Reduced mortality and moderate alcohol consumption: the phospholipase D-mTOR connection.
[20372065] Cell Cycle 9(7): 1291-4 (2010)

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.
[19098454] Cell Cycle 7(24): 3805-9 (2008)

All roads lead to mTOR: integrating inflammation and tumor angiogenesis.
[18073529] Cell Cycle 6(24): 3011-4 (2007)

The mTOR pathway in the control of protein synthesis.
[16990457] Physiology (Bethesda) 21(-): 362-9 (2006)

Of mice and men: therapeutic mTOR inhibition in polycystic kidney disease.
[20133481] J Am Soc Nephrol 21(3): 390-1 (2010)

The role of the mammalian target of rapamycin (mTOR) in renal disease.
[19875810] J Am Soc Nephrol 20(12): 2493-502 (2009)

Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
[20160148] Proc Am Thorac Soc 7(1): 48-53 (2010)

mTOR signaling at a glance.
[19812304] J Cell Sci 122(Pt 20): 3589-94 (2009)

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony.
[20231296] J Biol Chem 285(19): 14071-7 (2010)

New concepts in phospholipase D signaling in inflammation and cancer.
[20623096] ScientificWorldJournal 10(-): 1356-69 (2010)

An emerging role for IQGAP1 in regulating protein traffic.
[20495773] ScientificWorldJournal 10(-): 944-53 (2010)

Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: drug discovery for targeting the tumor microenvironment.
[21422725] J Pharmacol Sci 115(4): 446-52 (2011)

Signal transduction inhibitor therapy for lymphoma.
[21239804] Hematology Am Soc Hematol Educ Program 2010(-): 265-70 (2010)

mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?
[20350481] Discov Med 9(46): 173-8 (2010)

TOR-dependent control of autophagy: biting the hand that feeds.
[20006481] Curr Opin Cell Biol 22(2): 157-68 (2010)

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.
[21490404] J Clin Invest 121(4): 1231-41 (2011)

p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment.
[20182617] Cold Spring Harb Perspect Biol 2(2): a001057 (2010)

Regulation of autophagy by lysosomal positioning.
[21521941] Autophagy 7(8): 927-8 (2011)

The role of TOR in autophagy regulation from yeast to plants and mammals.
[18670193] Autophagy 4(7): 851-65 (2008)

mTOR regulation of autophagy.
[20083114] FEBS Lett 584(7): 1287-95 (2010)

Mammalian target of rapamycin inhibition.
[15448035] Clin Cancer Res 10(18 Pt 2): 6382S-7S (2004)

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
[14770419] Cancer 100(4): 657-66 (2004)

Regulation of mTOR by phosphatidic acid?
[17210675] Cancer Res 67(1): 1-4 (2007)

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.
[15365568] Br J Cancer 91(8): 1420-4 (2004)

Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.
[20498248] Clin J Am Soc Nephrol 5(7): 1312-29 (2010)

Targeting mTOR for the treatment of AML. New agents and new directions.
[21680954] Oncotarget 2(6): 510-7 (2011)

The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein.
[20399660] Trends Cell Biol 20(7): 427-34 (2010)

Immunoregulatory functions of mTOR inhibition.
[19390566] Nat Rev Immunol 9(5): 324-37 (2009)

With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging.
[20519118] Cell Metab 11(6): 453-65 (2010)

Ubiquitin-proteasome system inhibitors and AMPK regulation in hepatic cold ischaemia and reperfusion injury: possible mechanisms.
[22455352] Clin Sci (Lond) 123(2): 93-8 (2012)

Rheb/mTOR activation and regulation in cancer: novel treatment strategies beyond rapamycin.
[21561413] Curr Drug Targets 12(8): 1223-31 (2011)

Akt-dependent and -independent mechanisms of mTOR regulation in cancer.
[19166931] Cell Signal 21(5): 656-64 (2009)

Common mechanisms of PIKK regulation.
[19464237] DNA Repair (Amst) 8(9): 1004-8 (2009)

mTOR signaling: at the crossroads of plasticity, memory and disease.
[19963289] Trends Neurosci 33(2): 67-75 (2010)

Dysregulation of the mTOR pathway secondary to mutations or a hostile microenvironment contributes to cancer and poor wound healing.
[19209152] J Invest Dermatol 129(3): 529-31 (2009)

Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses.
[19229373] Curr Oncol 16(1): 59-61 (2009)

Targeting the mTOR signaling network for cancer therapy.
[19332717] J Clin Oncol 27(13): 2278-87 (2009)

Targeted therapy in lymphoma.
[21092307] J Hematol Oncol 3(-): 45 (2010)

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
[19860903] J Hematol Oncol 2(-): 45 (2009)

Mammalian target of rapamycin: a central node of complex signaling cascades.
[21738819] Int J Clin Exp Pathol 4(5): 476-95 (2011)

Enhancing mTOR-targeted cancer therapy.
[19694499] Expert Opin Ther Targets 13(10): 1193-203 (2009)

Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.
[18440854] Drug Resist Updat 11(3): 63-76 (2008)

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
[18166498] Drug Resist Updat 11(1-2): 32-50 (2008)

Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition.
[21041997] Cells Tissues Organs 193(1-2): 8-22 (2011)

Mechanisms of amino acid sensing in mTOR signaling pathway.
[20016704] Nutr Res Pract 3(1): 64-71 (2009)

Emerging evidence of a link between the polycystins and the mTOR pathways.
[19863783] Pathogenetics 2(1): 6 (2009)

Regulation of mTOR signaling in skeletal muscle hypertrophy.
[19147966] J Musculoskelet Neuronal Interact 8(4): 338-9 (2008)

mTOR signaling in glioblastoma: lessons learned from bench to bedside.
[20472883] Neuro Oncol 12(8): 882-9 (2010)

Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
[19817806] Epilepsia 51(1): 27-36 (2010)

The functions of mTOR in ischemic diseases.
[21871173] BMB Rep 44(8): 506-11 (2011)

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.
[20418915] Oncogene 29(26): 3733-44 (2010)

Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.
[20661228] Lab Invest 90(10): 1406-14 (2010)

The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway.
[18311165] Nat Rev Microbiol 6(4): 266-75 (2008)

mTOR signaling in cancer cell motility and tumor metastasis.
[20528734] Crit Rev Eukaryot Gene Expr 20(1): 1-16 (2010)

The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells.
[20666708] Crit Rev Immunol 30(4): 387-94 (2010)

mTOR: dissecting regulation and mechanism of action to understand human disease.
[19143634] Biochem Soc Trans 37(Pt 1): 213-6 (2009)

A complex interplay between Akt, TSC2 and the two mTOR complexes.
[19143635] Biochem Soc Trans 37(Pt 1): 217-22 (2009)

Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress.
[20965424] Mol Cell 40(2): 310-22 (2010)

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.
[21307646] Oxid Med Cell Longev 3(6): 374-91 (2010)

Frontier of epilepsy research - mTOR signaling pathway.
[21467839] Exp Mol Med 43(5): 231-74 (2011)

The complexes of mammalian target of rapamycin.
[20491627] Curr Protein Pept Sci 11(6): 409-24 (2010)

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.
[20535652] Curr Top Microbiol Immunol 347(-): 279-96 (2010)

The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.
[20870173] Immunity 33(3): 301-11 (2010)

A comprehensive map of the mTOR signaling network.
[21179025] Mol Syst Biol 6(): 453 (2010)

mTOR: from growth signal integration to cancer, diabetes and ageing.
[21157483] Nat Rev Mol Cell Biol 12(1): 21-35 (2011)

Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema.
[20473305] Nat Med 16(7):767-73 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\MTOR.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\MTOR.php on line 92